Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk

Molecular Carcinogenesis

Volumn 55, Issue 8, 2016, Pages 1251-1261

  Davenport, James R ^a   Cai, Qiuyin ^a,b   Ness, Reid M ^a,c   Milne, Ginger ^a   Zhao, Zhiguo ^a   Smalley, Walter E ^a,c   Zheng, Wei ^a,b,d   Shrubsole, Martha J ^a,b,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

Author keywords

biomarkers; C reactive protein; colorectal adenoma risk; inflammation; prostaglandin E2 Metabolite

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; CANCER RISK; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN URINE LEVEL; RISK ASSESSMENT;

EID: 84977566580     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22367     Document Type: Article

References (45)

1. Terzić J, Grivennikov S., Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138:2101–2114.
2. McLean MH, Murray GI, Stewart KN, et al. The inflammatory microenvironment in colorectal neoplasia. PLOS ONE 2011; 6:e15366.
3. Pepys MB, Hirshfield GM. C-reactive protein: A critical update. J Clin Invest 2003; 111:1805–1812.
4. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013; 56:131–142.
5. Wang MY, Zhou HH, Zhang SC, et al. Recurrent mutations at C-reactive protein gene promoter SNP position-286 in human cancers. Cell Res 2014; 24:505–508.
6. Su HX, Zhou HH, Wang MY, et al. Mutations of C-reactive protein (CRP)-286 SNP, APC and p53 in colorectal cancer: Implication for CRP-Wnt crosstalk. PLOS ONE 2014; 9:e102418.
7. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. J Am Med Assoc 2004; 291:585–590.
8. Zhang SM, Buring JM, Lee IM, Cook NR, Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 142:425–432.
9. Il'yasova, D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the healthy aging and body composition cohort. Cancer Epidem Biomar 2005; 14:2413–2418.
10. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66:2483–2487.
11. Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: A nested case-control study within the European prospective investigation into cancer and nutrition. Am J Epidemiol 2010; 172:407–418.
12. Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventative response to anti-inflammatory drugs. Gastroenterology 2011; 140:799–808.
13. Toriola AT, Cheng TY, Neuhouser ML, et al. Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers. Int J Cancer 2013; 132:2648–2658.
14. Wu J, Cai Q, Li H, et al. Circulating C-reactive protein and colorectal cancer risk: A report from the Shanghai men's health study. Carcinogenesis 2013; 34:2799–2803.
15. Chiu HM, Lin JT, Chen TH, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 2008; 103:2317–2325.
16. Tsilidis KK, Erlinger TP, Rifai N, et al. C-reactive protein and colorectal adenoma in the CLUE-II cohort. Cancer Cause Control 2008; 19:559–567.
17. Otake T, Uezono K, Takahashi R, et al. C-reactive protein and colorectal adenomas: Self defense forces health study. Cancer Sci 2009; 100:709–714.
18. Kim S, Keku TO, Martin C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68:323–328.
19. Ognjanovic S, Yamamoto J, Saltzman B, et al. Serum CRP and IL-6, genetic variants and risk of colorectal adenoma in a multi-ethnic population. Cancer Cause Control 2010; 21:1131–1138.
20. Chan AT, Sima CS, Zauber AG, Ridker, PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to Celecoxib treatment. Cancer Prev Res 2011; 4:1172–1180.
21. Gunter MJ, Cross AJ, Huang WY, et al. A prospective evaluation of C-reactive protein levels and colorectal adenoma development. Cancer Epidemiol Biomarkers 2011; 20:537–544.
22. Kong SY, Bostick RM, Flanders WD, et al. Oxidative balance score, colorectal adenoma, and markers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers 2012; 23:545–554.
23. Tao S, Haug U, Kuhn K, Brenner H. Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer 2012; 106:1424–1430.
24. Crockett SD, Mott LA, Barry EL, et al. C-reactive protein and risk of colorectal adenomas or serrated polyps: A prospective study. Cancer Prev Res 2014; 7:1122–1127.
25. O'Brien MJ, Winawer SJ, Zauber AG, et al. The national polyp study: Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98:371–379.
26. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: Meta-analysis of the randomized trials. J Natl Cancer I 2009; 101:256–266.
27. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873–884.
28. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885–895.
29. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of Rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131:1674–1682.
30. Shrubsole MJ, Cai Q, Wen W, et al. Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res 2012; 5:336–342.
31. Cai Q, Gao YT, Chow WH, et al. Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk. J Clin Oncology 2006; 24:5010–5016.
32. Johnson JC, Schmidt CR, Shrubsole MJ, et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol 2006; 4:1358–1365.
33. Bezawada N, Song M, Wu K, et al. Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventative response to anti-inflammatory drugs. Cancer Prev Res 2014; 7:758–765.
34. Maresso KC, Vilar E, Hawk ET. Urinary PGE-M in colorectal cancer: Predicting more than risk? Cancer Prev Res 2014; 7:969–972.
35. Shrubsole MJ, Wu H, Ness RM, Shyr Y, Smalley WE, Zheng W. Alcohol drinking, cigarette smoking, and risk of colorectal adenomatous and hyperplastic polyps. Am J Epidemiol 2008; 167:1050–1058.
36. Buchowski MS, Schlundt DG, Hargreaves MK, Hankin JH, Signorello LB, Blot WJ. Development of a culturally sensitive food frequency questionnaire for use in the Southern Community Cohort Study. Cell Mol Biol 2003; 49:1295–1304.
37. Ikonomidas I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100:793–798.
38. Kim SB, Kim SH, Chang JW, et al. Effects of celecoxib on high-sensitivity C-reactive protein levels in chronic peritoneal dialysis patients. Renal Failure 2004; 26:381–384.
39. Hornung RW, Reed LD. Estimation of average concentration in the presence of non-detectable values. Appl Occup Environ Hyg 1990; 5:46–51.
40. Murphey LC, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE-2 by a liquid chromatographic/mass spectrometric assay: Determination of cyclooxygenase specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem 2004; 334:266–275.
41. Grivennikov S, Karin E, Terzic J, et al. IL-6 and STAT-3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15:103–113.
42. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118:560–570.
43. Greenhough A, Smartt HJ, Moore AE, et al. The COX2/PGE2 pathway: Key roles in the hallmark of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30:377–386.
44. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: The role of prostaglandin E2. Oncology 2005; 69:28–32.
45. Sung KC. Seasonal variation of C-reactive protein in apparently healthy Koreans. Int J Cardiol 2006; 107:338–342.